Baxalta hemophilia product line Adds a new member

FDA recently announced the approval of a long-term Baxalta hemophilia A therapy Adynovate market, which is Baxalta since its predecessor company Baxter split out another good news in the field of blood diseases. This therapy is currently selling the drug Advate Baxalta company's long-term upgrade, while the latter is the world's best-selling class of drugs currently coagulation factor XIII.
Prior Baxalta to Adynovate (BAX855) high hopes that this product will help the company to further consolidate its market position in hemophilia, and with Biogen company launched similar products in the same stage last year. It is understood that patients receiving treatment Adynovate only need two injections a week, it can achieve normal blood coagulation promote wound effect.
However, Baxalta want a monopoly would not be easy in the hemophilia market. In addition to their old rival Biogen, Bayer similar products BAY 81-8973 is currently also awaiting FDA approval. In addition, Novo Nordisk also has a similar product is in phase III clinical study.
However, for Baxalta is another big positive is the Adynovate approved the acquisition will help the company resist the pressure Shire. As we all know, after Baxter split, Shire proposed acquisition Baxalta company's offer, the entire acquisition price has reached as much as $ 30 billion. However, just do not want to live on their own Baxalta apparently so quickly by other companies incorporated, company CEO Ludwig Hantson has repeatedly publicly turned down the acquisition. Shire's order to break even read like, Hantson also proposed a ambitious product development program and I hope that by 2020 the company launched 20 new products to market, so the company's annual sales to as much as $ 8.5 billion.